THE EFFECTIVENESS OF TREATMENT OF ASCITES DUE TO RECURRENCE OF PLATINUM-REFRACTORY OVARIAN CANCER USING METRONOMIC CHEMOTHERAPY
Keywords:
ovarian cancer, lymph node dissection, cytoreduction, metastasis, platinum-sensitive and platinum-resistant recurrenceAbstract
Ovarian cancer (OC) remains the leading cause of death from gynecological cancer. The initial treatment for IC-IV stages of OC includes surgical cytoreduction followed by platinum-containing chemotherapy. The best outcomes are observed in patients, in whom complete cytoreduction has been achieved. Despite this fact, most patients develop relapses and the 5-year survival rate is about 30 %. The frequency of lymph node involvement in patients with recurrent OC is not reliably known; isolated lymph node recurrence is reported to occur in 5–32 % of patients. To date, the problem regarding the extent of lymph node dissection in treatment of OC recurrence is still unsolved. In our paper we review the available data concerning the role of secondary cytoreductive surgery for isolated lymph node recurrence of ovarian cancer. Isolated lymph node recurrence of ovarian cancer may indicate a more favorable prognosis and has a less aggressive pattern of OC relapse. The role of secondary cytoreduction in this context is not fully understood, but this category of patients may be one of the most suitable for surgical treatment of ovarian cancer recurrence.
References
Ahmed N., Stenvers K.L. Getting to know ovarian cancer ascites: opportunities for targeted therapy based translational research. Front Oncol. 2013 Sep 25; 3: 256. doi: 10.3389/fonc.2013.00256.
Ardatskaya M.D. Ascites and peritonitis in the practice of therapist and gastro enterologist. Consilium Medicum. 2009; 11 (8): 51–60. (in Russian).
Abdurakhmonov Jurabek, Rahimov Nodir, Shakhanova Shakhnoza. Modern view on ascite in ovarian cancer. Journal of Biomedicine and Practice. 2022, vol. 7, issue 4, pp. 130-139
Caitlin Hodge, Brian D Badgwell Palliation of Malignant Ascites Surg Oncol 2019 Jul;120(1):67-73 doi: 10.
Shakhanova Sh. Shakhnoza, Rakhimov M. Nodir. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // Journal of Biomedicine and Practice. 2023, vol. 8, issue 3, pp. 406-417 15.
Rakhimov M. Nodir, Khudayberdiyeva A. Shohista, Oripova R. Mehriniso, Shakhanova Sh. Shakhnoza. Practical recommendations forNutritional support for cervical cancer// Journal of Biomedicine and Practice. 2023, vol. 8, issue 2,pp.224-230 17.
Larissa Meyer , Rudy Suidan, Charlotte Sun, Shannon Westin, Robert L Coleman The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer// Expert Review of Quality of Life in Cancer Care. Author manuscript; available in PMC 2019 March 20. doi:10.1080/23809000.2016.1185369.
Latifi A., Luwor R.B., Bilandzic M., Nazaretian S., Stenvers K., Pyman J., Zhu H., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012; 7 (10): e46858. doi: 10.1371/journal.pone.0046858 19.
Shield K., Ackland M.L., Ahmed N., Rice G.E. Multicellular spher oids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 2009 Apr; 113 (1): 143–8. doi: 10.1016/j.ygyno.2008.11.032. 23.
Smolle E., Taucher V., Haybaeck J. Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. Anticancer Res. 2014 Apr; 34 (4): 1553–614 24. Stepanov I.V ., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; 5: 45–53. (in Russian).
Stepanov S.O., Mitina L.A., Guts O.V., Bespalov P.D. Ultrasound imaging of peritoneal dissemination. Diagnostic radiology and radiotherapy. 2013; 3 (4): 66–70. (in Russian)
Tan D.S., Agarwal R., Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 7 (11): 939–1. doi: 10.1016/S1470 2045(06)70939 1. 27.
